Conflicts of interest
TY
ONCOLOGY
ST has nothing to disclose. YK has nothing to disclose. YC has nothing to disclose. TM has nothing to disclose. TK has received grants from PACT Pharma, and personal fees from Chugai, and Sysmex. KS has received personal fees from Pfizer, Eisai, and AstraZeneca. TY has received grants from AMGEN, AstraZeneca, Takeda, Daiichi Sankyo, ONO Pharmaceutical Co., Ltd, MSD, Abbvie, Novartis, Chugai, Merck, Blueprint, and BMS, and personal fees from AstraZeneca, Takeda, Boehringer-Ingelheim, TAIHO, Chugai, Novartis, Lilly, MSD, ONO Pharmaceutical Co., Ltd, Roche, ArcherDX, Invitae, and BMS. SK has received grants from Chugai, Takeda, ASLAN, AstraZeneca, Eisai, Pfizer, Boehringer Ingelheim, Incyte, Lilly, Bristol Myers Squibb, MSD, and Astellas, and personal fees from Chugai, Takeda, Termo, Incyte, and Eisai. SI has received personal fees from Daiichi-Sankyo, Lilly, ONO Pharmaceutical Co., Ltd, Chugai, and Taiho. KY has received personal fees from Pfizer, Eisai, AstraZeneca, Lilly, Takeda, Chugai, Fuji Film Pharma, Novartis, and Genmab. TS has received grants from Novartis, Lilly, Daiichi-Sankyo, Abbvie, Bristol-Myers Squibb, Eisai, AstraZeneca, Pfizer, Loxo Oncology, Takeda, Incyte, Chordia Therapeutics, 3D-Medicine, Symbio Pharmaceuticals, PharmaMar, Five Prime, and Astellas, and personal fees from Lilly, MSD, Chugai, Abbvie, Daiichi-Sankyo, Takeda, and Chordia Therapeutics. NY has received grants from Chugai, Taiho, Eisai, Lilly, Quintiles, Astellas, BMS, Novartis, Daiichi-Sankyo, Pfizer, Boehringer Ingelheim, Kyowa-Hakko Kirin, Bayer, ONO Pharmaceutical Co., Ltd, Takeda, Janssen Pharma, MSD, Merck, GSK, Sumitomo Dainippon, Chiome Bioscience Inc., Otsuka, Carna Biosciences, Genmab, and Shionogi, and personal fees from ONO Pharmaceutical Co., Ltd, Chugai, AstraZeneca, Pfizer, Lilly, BMS, Eisai, Otsuka, Takeda, Boehringer Ingelheim, Cimic, and Sysmex. SS has received personal fees from ONO Pharmaceutical Co., Ltd.